Seeking Alpha

Nektar Therapeutics (NKTR +2.1%) says that a Phase 1a clinical study of its drug candidate...

Nektar Therapeutics (NKTR +2.1%) says that a Phase 1a clinical study of its drug candidate NKTR-192, a short-acting mu-opioid analgesic for the treatment of acute pain, achieved its target pharmacokinetic profile. The company also says that dosing has commenced in a second Phase 1a clinical study which will explore the pharmacodynamic profile of the drug in healthy subjects.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|